STUDY SEARCH RESULTS

1 study found for your search request:  6482-022

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Pa...
Condition: Carcinoma, Renal Cell
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT05239728
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site